<H1>Chapter DOI: 10.1007/978-1-60327-829-4_26<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>229</td></tr><tr><td>Springer references</td><td>7</td></tr><tr><td>Non Springer references</td><td>222</td></tr><tr><td>BibStructured Count</td><td width="10%">229</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>128</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>2</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>7</td></tr><tr><td>DOI Obtained For Non Springer</td><td>123</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>130</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>119</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_26</td><td>BibArticle</td><td>Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992;70(12):2861&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19921215)70:12%3C2861::AID-CNCR2820701224%3E3.0.CO;2-G>10.1002/1097-0142(19921215)70:12%3C2861::AID-CNCR2820701224%3E3.0.CO;2-G</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR2_26</td><td>BibArticle</td><td>Luscombe CJ, et al. Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001;85(10):1504&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_26</td><td>BibArticle</td><td>Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94(6):1867&#8211;75.</td><td><a href=http://dx.doi.org/10.1002/cncr.10427>10.1002/cncr.10427</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR4_26</td><td>BibArticle</td><td>Corder EH, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2(5):467&#8211;72.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_26</td><td>BibArticle</td><td>Gann PH, et al. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5(2):121&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_26</td><td>BibArticle</td><td>Jacobs ET, et al. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 2004;89&#8211;90(1&#8211;5):533&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2004.03.063>10.1016/j.jsbmb.2004.03.063</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR7_26</td><td>BibArticle</td><td>Nomura AM, et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 1998;9(4):425&#8211;32.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_26</td><td>BibArticle</td><td>Platz EA, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15(3):255&#8211;65.</td><td><a href=http://dx.doi.org/10.1023/B:CACO.0000024245.24880.8a>10.1023/B:CACO.0000024245.24880.8a</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR9_26</td><td>BibArticle</td><td>Ahonen MH, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11(9):847&#8211;52.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10_26</td><td>BibArticle</td><td>Tuohimaa P, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108(1):104&#8211;8.</td><td><a href=http://dx.doi.org/10.1002/ijc.11375>10.1002/ijc.11375</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR11_26</td><td>BibArticle</td><td>Chan JM, et al. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 1998;9(6):559&#8211;66.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12_26</td><td>BibArticle</td><td>Chan JM, et al. Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 2000;11(9):859&#8211;67.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_26</td><td>BibArticle</td><td>Giovannucci E, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998;58(3):442&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_26</td><td>BibArticle</td><td>Kristal AR, et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11(8):719&#8211;25.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_26</td><td>BibArticle</td><td>Park SY, et al. Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007;166(11):1259&#8211;69.</td><td><a href=http://dx.doi.org/10.1093/aje/kwm269>10.1093/aje/kwm269</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR16_26</td><td>BibArticle</td><td>Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 2008;60(4):421&#8211;41.</td><td><a href=http://dx.doi.org/10.1080/01635580801911779>10.1080/01635580801911779</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID, IssueID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR17_26</td><td>BibArticle</td><td>Qin LQ, et al. Milk consumption is a risk factor for prostate cancer: meta-analysis of case-control studies. Nutr Cancer 2004;48(1):22&#8211;7.</td><td><a href=http://dx.doi.org/10.1207/s15327914nc4801_4>10.1207/s15327914nc4801_4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR18_26</td><td>BibArticle</td><td>Cross HS, et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001;66(3&#8211;5):287&#8211;92.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_26</td><td>BibArticle</td><td>Tangpricha V, et al. 25-Hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001;357(9269):1673&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_26</td><td>BibArticle</td><td>Chen TC, et al. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003;88(2):315&#8211;22.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_26</td><td>BibArticle</td><td>Hsu JY, et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001;61(7):2852&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22_26</td><td>BibArticle</td><td>Bouillon RA, et al. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr 1987;45(4):755&#8211;63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_26</td><td>BibArticle</td><td>Dandona P, et al. Low 1,25-dihydroxyvitamin D, secondary hyperparathyroidism, and normal osteocalcin in elderly subjects. J Clin Endocrinol Metab 1986;63(2):459&#8211;62.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24_26</td><td>BibArticle</td><td>Dubbelman R, et al. Age-dependent vitamin D status and vertebral condition of white women living in Curacao (The Netherlands Antilles) as compared with their counterparts in The Netherlands. Am J Clin Nutr 1993;58(1):106&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25_26</td><td>BibArticle</td><td>Lips P, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124(4):400&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_26</td><td>BibArticle</td><td>Giovannucci E. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 1998;9(6):567&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27_26</td><td>BibArticle</td><td>Beer TM, et al. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2004;13(12):2225&#8211;32.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28_26</td><td>BibArticle</td><td>Kidd LC, et al. Sequence variation within the 5&#8242; regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate 2005;64(3):272&#8211;82.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/pros.20204>10.1002/pros.20204</a></td><td><b>CrossRef-Web</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR29_26</td><td>BibArticle</td><td>Torkko KC, et al. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 2008;14(10):3223&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-4894>10.1158/1078-0432.CCR-07-4894</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR30_26</td><td>BibArticle</td><td>Zhou W, et al. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14(10):2303&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1055-9965.EPI-05-0335>10.1158/1055-9965.EPI-05-0335</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, IssueID, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR31_26</td><td>BibArticle</td><td>Robsahm TE, et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004;15(2):149&#8211;58.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32_26</td><td>BibArticle</td><td>Lagunova Z, et al. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007;67(12):1362&#8211;70.</td><td><a href=http://dx.doi.org/10.1002/pros.20577>10.1002/pros.20577</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR33_26</td><td>BibArticle</td><td>Mangelsdorf DJ, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83(6):835&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/0092-8674(95)90199-X>10.1016/0092-8674(95)90199-X</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR34_26</td><td>BibArticle</td><td>Carlberg C, Saurat JH. Vitamin D-retinoid association: molecular basis and clinical applications. J Investig Dermatol Symp Proc 1996;1(1):82&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR35_26</td><td>BibArticle</td><td>Conde I, et al. Expression of vitamin D3 receptor and retinoid receptors in human breast cancer: identification of potential heterodimeric receptors. Int J Oncol 2004;25(4):1183&#8211;91.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR36_26</td><td>BibArticle</td><td>Kliewer SA, et al. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992;355(6359):446&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/355446a0>10.1038/355446a0</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, IssueID, VolumeID, FirstPage, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR37_26</td><td>BibArticle</td><td>Nanes MS, et al. A single up-stream element confers responsiveness to 1,25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene. Endocrinology 1994;134(3):1113&#8211;20.</td><td><a href=http://dx.doi.org/10.1210/endo.134.3.8119149>10.1210/endo.134.3.8119149</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, ArticleTitle, JournalTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR38_26</td><td>BibArticle</td><td>Koszewski NJ, Reinhardt TA, Horst RL. Vitamin D receptor interactions with the murine osteopontin response element. J Steroid Biochem Mol Biol 1996;59(5&#8211;6):377&#8211;88.</td><td><a href=http://dx.doi.org/10.1016/S0960-0760(96)00127-6>10.1016/S0960-0760(96)00127-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR39_26</td><td>BibArticle</td><td>Kim RH, et al. Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Biochem J 1996;318(Pt 1):219&#8211;26.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1042/bj3180219>10.1042/bj3180219</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR40_26</td><td>BibArticle</td><td>Kitazawa R, Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun 2002;290(2):650&#8211;5.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1006/bbrc.2001.6251>10.1006/bbrc.2001.6251</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR41_26</td><td>BibArticle</td><td>Drissi H, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002;274(2):323&#8211;33.</td><td><a href=http://dx.doi.org/10.1006/excr.2002.5474>10.1006/excr.2002.5474</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR42_26</td><td>BibArticle</td><td>Hakim I, Bar-Shavit Z. Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem 2003;88(5):986&#8211;98.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR43_26</td><td>BibArticle</td><td>Hawa NS, O&#8217;Riordan JL, Farrow SM. Functional analysis of vitamin D response elements in the parathyroid hormone gene and a comparison with the osteocalcin gene. Biochem Biophys Res Commun 1996;228(2):352&#8211;7.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1996.1665>10.1006/bbrc.1996.1665</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR44_26</td><td>BibArticle</td><td>Falzon M. DNA sequences in the rat parathyroid hormone-related peptide gene responsible for 1,25-dihydroxyvitamin D3-mediated transcriptional repression. Mol Endocrinol 1996;10(6):672&#8211;81.</td><td><a href=http://dx.doi.org/10.1210/mend.10.6.8776727>10.1210/mend.10.6.8776727</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR45_26</td><td>BibArticle</td><td>Maestro B, et al. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003;84(2&#8211;3):223&#8211;30.</td><td><a href=http://dx.doi.org/10.1016/S0960-0760(03)00032-3>10.1016/S0960-0760(03)00032-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR46_26</td><td>BibArticle</td><td>Lee S, et al. Identification of a functional vitamin D response element in the murine Insig-2 promoter and its potential role in the differentiation of 3T3-L1 preadipocytes. Mol Endocrinol 2005;19(2):399&#8211;408.</td><td><a href=http://dx.doi.org/10.1210/me.2004-0324>10.1210/me.2004-0324</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR47_26</td><td>BibArticle</td><td>Quelo I, Machuca I, Jurdic P. Identification of a vitamin D response element in the proximal promoter of the chicken carbonic anhydrase II gene. J Biol Chem 1998;273(17):10638&#8211;46.</td><td><a href=http://dx.doi.org/10.1074/jbc.273.17.10638>10.1074/jbc.273.17.10638</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR48_26</td><td>BibArticle</td><td>Seoane S, et al. Localization of a negative vitamin D response sequence in the human growth hormone gene. Biochem Biophys Res Commun 2002;292(1):250&#8211;5.</td><td><a href=http://dx.doi.org/10.1006/bbrc.2002.6641>10.1006/bbrc.2002.6641</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR49_26</td><td>BibArticle</td><td>Gill RK, Christakos S. Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl Acad Sci U S A 1993;90(7):2984&#8211;8.</td><td><a href=http://dx.doi.org/10.1073/pnas.90.7.2984>10.1073/pnas.90.7.2984</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR50_26</td><td>BibArticle</td><td>Fujisawa K, et al. Identification of a response element for vitamin D3 and retinoic acid in the promoter region of the human fructose-1,6-bisphosphatase gene. J Biochem 2000;127(3):373&#8211;82.</td><td><a href=http://dx.doi.org/10.1093/oxfordjournals.jbchem.a022618>10.1093/oxfordjournals.jbchem.a022618</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR51_26</td><td>BibArticle</td><td>Liu M, et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10(2):142&#8211;53.</td><td><a href=http://dx.doi.org/10.1101/gad.10.2.142>10.1101/gad.10.2.142</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR52_26</td><td>BibArticle</td><td>Jiang F, et al. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 2003;278(48):48030&#8211;40.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR53_26</td><td>BibArticle</td><td>Matilainen M, et al. Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res 2005;33(17):5521&#8211;32.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR54_26</td><td>BibArticle</td><td>Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004;18(5):1109&#8211;19.</td><td><a href=http://dx.doi.org/10.1210/me.2003-0344>10.1210/me.2003-0344</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR55_26</td><td>BibArticle</td><td>Zierold C, Darwish HM, DeLuca HF. Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. Proc Natl Acad Sci U S A 1994;91(3):900&#8211;2.</td><td><a href=http://dx.doi.org/10.1073/pnas.91.3.900>10.1073/pnas.91.3.900</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR56_26</td><td>BibArticle</td><td>Thompson PD, et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 2002;299(5):730&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(02)02742-0>10.1016/S0006-291X(02)02742-0</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR57_26</td><td>BibArticle</td><td>McCarthy TC, Li X, Sinal CJ. Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 2005;280(24):23232&#8211;42.</td><td><a href=http://dx.doi.org/10.1074/jbc.M411520200>10.1074/jbc.M411520200</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR58_26</td><td>BibArticle</td><td>McGaffin KR, Chrysogelos SA. Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol 2005;35(1):117&#8211;33.</td><td><a href=http://dx.doi.org/10.1677/jme.1.01813>10.1677/jme.1.01813</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR59_26</td><td>BibArticle</td><td>Candeliere GA, et al. A composite element binding the vitamin D receptor, retinoid X receptor alpha, and a member of the CTF/NF-1 family of transcription factors mediates the vitamin D responsiveness of the c-fos promoter. Mol Cell Biol 1996;16(2):584&#8211;92.</td><td><a href=http://dx.doi.org/10.1128/MCB.16.2.584>10.1128/MCB.16.2.584</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR60_26</td><td>BibArticle</td><td>Xie Z, Bikle DD. Differential regulation of vitamin D responsive elements in normal and transformed keratinocytes. J Invest Dermatol 1998;110(5):730&#8211;3.</td><td><a href=http://dx.doi.org/10.1046/j.1523-1747.1998.00175.x>10.1046/j.1523-1747.1998.00175.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR61_26</td><td>BibArticle</td><td>Polly P, et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem 1996;60(3):322&#8211;33.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-4644(19960301)60:3%3C322::AID-JCB4%3E3.3.CO;2-4>10.1002/(SICI)1097-4644(19960301)60:3%3C322::AID-JCB4%3E3.3.CO;2-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR62_26</td><td>BibArticle</td><td>Cao X, et al. Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. J Biol Chem 1993;268(36):27371&#8211;80.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR63_26</td><td>BibArticle</td><td>Bikle DD, et al. The vitamin D response element of the involucrin gene mediates its regulation by 1,25-dihydroxyvitamin D3. J Invest Dermatol 2002;119(5):1109&#8211;13.</td><td><a href=http://dx.doi.org/10.1046/j.1523-1747.2002.19508.x>10.1046/j.1523-1747.2002.19508.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR64_26</td><td>BibArticle</td><td>Deftos LJ, et al. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005;327(2):468&#8211;72.</td><td><a href=http://dx.doi.org/10.1016/j.bbrc.2004.11.162>10.1016/j.bbrc.2004.11.162</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR65_26</td><td>BibArticle</td><td>Lynch CC, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7(5):485&#8211;96.</td><td><a href=http://dx.doi.org/10.1016/j.ccr.2005.04.013>10.1016/j.ccr.2005.04.013</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR66_26</td><td>BibArticle</td><td>Tenta R, et al. Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res 2005;37(10):593&#8211;601.</td><td><a href=http://dx.doi.org/10.1055/s-2005-870525>10.1055/s-2005-870525</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR67_26</td><td>BibArticle</td><td>Nemere I, Yoshimoto Y, Norman AW. Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D3. Endocrinology 1984;115(4):1476&#8211;83.</td><td><a href=http://dx.doi.org/10.1210/endo-115-4-1476>10.1210/endo-115-4-1476</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_2, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR68_26</td><td>BibArticle</td><td>De Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal 1994;6(7):717&#8211;24.</td><td><a href=http://dx.doi.org/10.1016/0898-6568(94)00042-5>10.1016/0898-6568(94)00042-5</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR69_26</td><td>BibArticle</td><td>Edelman A, Garabedian M, Anagnostopoulos T. Mechanisms of 1,25(OH)2D3-induced rapid changes of membrane potential in proximal tubule: role of Ca2+-dependent K+ channels. J Membr Biol 1986;90(2):137&#8211;43.</td><td><a href=http://dx.doi.org/10.1007/BF01869931>10.1007/BF01869931</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR70_26</td><td>BibArticle</td><td>Beno DW, et al. Protein kinase C and mitogen-activated protein kinase are required for 1,25-dihydroxyvitamin D3-stimulated Egr induction. J Biol Chem 1995;270(8):3642&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR71_26</td><td>BibArticle</td><td>de Boland AR, et al. Age-associated decrease in inositol 1,4,5-trisphosphate and diacylglycerol generation by 1,25(OH)2-vitamin D3 in rat intestine. Cell Signal 1996;8(3):153&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR72_26</td><td>BibArticle</td><td>de Boland AR, Morelli S, Boland R. 1,25(OH)2-vitamin D3 signal transduction in chick myoblasts involves phosphatidylcholine hydrolysis. J Biol Chem 1994;269(12):8675&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73_26</td><td>BibArticle</td><td>Capiati DA, et al. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells. J Cell Biochem 2004;93(2):384&#8211;97.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR74_26</td><td>BibArticle</td><td>Gniadecki R. Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes. J Invest Dermatol 1996;106(6):1212&#8211;7.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/1523-1747.ep12348498>10.1111/1523-1747.ep12348498</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR75_26</td><td>BibArticle</td><td>Park WH, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000;109(3):576&#8211;83.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2141.2000.02046.x>10.1046/j.1365-2141.2000.02046.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR76_26</td><td>BibArticle</td><td>Rossi AM, et al. MAPK inhibition by 1alpha,25(OH)2-vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src. J Steroid Biochem Mol Biol 2004;89&#8211;90(1&#8211;5):287&#8211;90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR77_26</td><td>BibArticle</td><td>Bellido T, et al. Evidence for the participation of protein kinase C and 3&#8242;,5&#8242;-cyclic AMP-dependent protein kinase in the stimulation of muscle cell proliferation by 1,25-dihydroxy-vitamin D3. Mol Cell Endocrinol 1993;90(2):231&#8211;8.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/0303-7207(93)90156-e>10.1016/0303-7207(93)90156-e</a></td><td><b>CrossRef-Web</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR78_26</td><td>BibArticle</td><td>Vazquez G, Boland R, de Boland AR. Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts. Biochim Biophys Acta 1995;1269(1):91&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/0167-4889(95)00097-C>10.1016/0167-4889(95)00097-C</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR79_26</td><td>BibArticle</td><td>Massheimer V, Boland R, de Boland AR. Rapid 1,25(OH)2-vitamin D3 stimulation of calcium uptake by rat intestinal cells involves a dihydropyridine-sensitive cAMP-dependent pathway. Cell Signal 1994;6(3):299&#8211;304.</td><td><a href=http://dx.doi.org/10.1016/0898-6568(94)90034-5>10.1016/0898-6568(94)90034-5</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR80_26</td><td>BibArticle</td><td>Santillan GE, Boland RL. Studies suggesting the participation of protein kinase A in 1,25(OH)2-vitamin D3-dependent protein phosphorylation in cardiac muscle. J Mol Cell Cardiol 1998;30(2):225&#8211;33.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1006/jmcc.1997.0577>10.1006/jmcc.1997.0577</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR81_26</td><td>BibArticle</td><td>Hmama Z, et al. 1Alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med 1999;190(11):1583&#8211;94.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR82_26</td><td>BibArticle</td><td>Lee JS, et al. Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA. Silencing of the p110alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide. J Biol Chem 2004;279(10):9379&#8211;88.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR83_26</td><td>BibArticle</td><td>Bektas M, Orfanos CE, Geilen CC, et al. Different vitamin D analogues induce sphingomyelin hydrolysis and apoptosis in the human keratinocyte cell line HaCaT. Cell Mol Biol (Noisy-le-grand) 2004;46(1):111&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84_26</td><td>BibArticle</td><td>Rebsamen MC, et al. 1Alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002;91(1):17&#8211;24.</td><td><a href=http://dx.doi.org/10.1161/01.RES.0000025269.60668.0F>10.1161/01.RES.0000025269.60668.0F</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR85_26</td><td>BibArticle</td><td>Schwartz Z, et al. 1Alpha,25-dihydroxyvitamin D(3) and 24R, 25-dihydroxyvitamin D(3) modulate growth plate chondrocyte physiology via protein kinase C-dependent phosphorylation of extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase. Endocrinology 2002;143(7):2775&#8211;86.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR86_26</td><td>BibArticle</td><td>Erben RG, et al. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 2002;16(7):1524&#8211;37.</td><td><a href=http://dx.doi.org/10.1210/mend.16.7.0866>10.1210/mend.16.7.0866</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR87_26</td><td>BibArticle</td><td>Huhtakangas JA, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 2004;18(11):2660&#8211;71.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88_26</td><td>BibArticle</td><td>Mizwicki MT, et al. Evidence that annexin II is not a putative membrane receptor for 1alpha,25(OH)2-vitamin D3. J Cell Biochem 2004;91(4):852&#8211;63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89_26</td><td>BibArticle</td><td>Norman AW, et al. Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R, 25(OH)2-vitamin D3. Mol Cell Endocrinol 2002;197(1&#8211;2):1&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR90_26</td><td>BibArticle</td><td>Norman AW, et al. Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1alpha,25-dihydroxyvitamin D3 indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses. Mol Endocrinol 1997;11(10):1518&#8211;31.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR91_26</td><td>BibArticle</td><td>Rohe B, et al. Identification and characterization of 1,25D3-membrane-associated rapid response, steroid (1,25D3-MARRS)-binding protein in rat IEC-6 cells. Steroids 2005;70(5&#8211;7):458&#8211;63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR92_26</td><td>BibArticle</td><td>Abe E, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981;78(8):4990&#8211;4.</td><td><a href=http://dx.doi.org/10.1073/pnas.78.8.4990>10.1073/pnas.78.8.4990</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR93_26</td><td>BibArticle</td><td>Konety BR, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001;165(1):253&#8211;8.</td><td><a href=http://dx.doi.org/10.1097/00005392-200101000-00074>10.1097/00005392-200101000-00074</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR94_26</td><td>BibArticle</td><td>Colston KW, et al. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992;44(4):693&#8211;702.</td><td><a href=http://dx.doi.org/10.1016/0006-2952(92)90405-8>10.1016/0006-2952(92)90405-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR95_26</td><td>BibArticle</td><td>Cross HS, Huber C, Peterlik M. Antiproliferative effect of 1,25-dihydroxyvitamin D3 and its analogs on human colon adenocarcinoma cells (CaCo-2): influence of extracellular calcium. Biochem Biophys Res Commun 1991;179(1):57&#8211;62.</td><td><a href=http://dx.doi.org/10.1016/0006-291X(91)91333-8>10.1016/0006-291X(91)91333-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR96_26</td><td>BibArticle</td><td>Yabushita H, et al. Vitamin D receptor in endometrial carcinoma and the differentiation-inducing effect of 1,25-dihydroxyvitamin D3 on endometrial carcinoma cell lines. J Obstet Gynaecol Res 1996;22(6):529&#8211;39.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR97_26</td><td>BibArticle</td><td>Fujioka T, et al. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. J Urol 1998;160(1):247&#8211;51.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)63098-2>10.1016/S0022-5347(01)63098-2</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR98_26</td><td>BibArticle</td><td>Nagakura K, et al. Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line. Kidney Int 1986;29(4):834&#8211;40.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR99_26</td><td>BibArticle</td><td>Higashimoto Y, et al. 1 Alpha,25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 1996;16(5A):2653&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR100_26</td><td>BibArticle</td><td>Zugmaier G, et al. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer 1996;73(11):1341&#8211;6.</td><td><a href=http://dx.doi.org/10.1038/bjc.1996.256>10.1038/bjc.1996.256</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, FirstPage, VolumeID, IssueID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR101_26</td><td>BibArticle</td><td>Getzenberg RH, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50(6):999&#8211;1006.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(97)00408-1>10.1016/S0090-4295(97)00408-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR102_26</td><td>BibArticle</td><td>Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58(3):277&#8211;88.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR103_26</td><td>BibArticle</td><td>Peehl DM, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994;54(3):805&#8211;10.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR104_26</td><td>BibArticle</td><td>Schwartz GG, et al. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994;14(3A):1077&#8211;81.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR105_26</td><td>BibArticle</td><td>Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995;136(1):20&#8211;6.</td><td><a href=http://dx.doi.org/10.1210/endo.136.1.7530193>10.1210/endo.136.1.7530193</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, Author_FamilyName_2, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR106_26</td><td>BibArticle</td><td>Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132(5):1952&#8211;60.</td><td><a href=http://dx.doi.org/10.1210/endo.132.5.7682937>10.1210/endo.132.5.7682937</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, JournalTitle, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR107_26</td><td>BibArticle</td><td>Zhuang SH, et al. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 1997;126(1):83&#8211;90.</td><td><a href=http://dx.doi.org/10.1016/S0303-7207(96)03974-3>10.1016/S0303-7207(96)03974-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR108_26</td><td>BibArticle</td><td>Shabahang M, et al. The effect of 1,25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Ann Surg Oncol 1996;3(2):144&#8211;9.</td><td><a href=http://dx.doi.org/10.1007/BF02305793>10.1007/BF02305793</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR109_26</td><td>BibArticle</td><td>Hara K, et al. Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res 2001;21(1A):321&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR110_26</td><td>BibArticle</td><td>Tokuumi Y. Correlation between the concentration of 1,25 alpha dihydroxyvitamin D3 receptors and growth inhibition, and differentiation of human osteosarcoma cells induced by vitamin D3. Nippon Seikeigeka Gakkai Zasshi 1995;69(4):181&#8211;90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR111_26</td><td>BibArticle</td><td>Celli A, Treves C, Stio M. Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation. Neurochem Int 1999;34(2):117&#8211;24.</td><td><a href=http://dx.doi.org/10.1016/S0197-0186(98)00075-8>10.1016/S0197-0186(98)00075-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR112_26</td><td>BibArticle</td><td>Veenstra TD, et al. Effects of 1,25-dihydroxyvitamin D3 on growth of mouse neuroblastoma cells. Brain Res Dev Brain Res 1997;99(1):53&#8211;60.</td><td><a href=http://dx.doi.org/10.1016/S0165-3806(96)00196-4>10.1016/S0165-3806(96)00196-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR113_26</td><td>BibArticle</td><td>Naveilhan P, et al. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? J Neurosci Res 1994;37(2):271&#8211;7.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/jnr.490370212>10.1002/jnr.490370212</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR114_26</td><td>BibArticle</td><td>Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981;108(3):1083&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR115_26</td><td>BibArticle</td><td>Hershberger PA, et al. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 1999;59(11):2644&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR116_26</td><td>BibArticle</td><td>McGuire TF, Trump DL, Johnson CS, et al. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 2001;276(28):26365&#8211;73.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1074/jbc.M010101200>10.1074/jbc.M010101200</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, FirstPage, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR117_26</td><td>BibArticle</td><td>Berger U, et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988;67(3):607&#8211;13.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1210/jcem-67-3-607>10.1210/jcem-67-3-607</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR118_26</td><td>BibArticle</td><td>Holick MF. Vitamin D: a millennium perspective. J Cell Biochem 2003;88(2):296&#8211;307.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/jcb.10338>10.1002/jcb.10338</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR119_26</td><td>BibArticle</td><td>Campbell MJ, Koeffler HP. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 1997;89(3):182&#8211;5.</td><td><a href=http://dx.doi.org/10.1093/jnci/89.3.182>10.1093/jnci/89.3.182</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR120_26</td><td>BibArticle</td><td>Sheikh MS, Rochefort H, Garcia M. Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 1995;11(9):1899&#8211;905.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR121_26</td><td>BibArticle</td><td>Wang QM, Jones JB, Studzinski GP. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996;56(2):264&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR122_26</td><td>BibArticle</td><td>Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139(3):1197&#8211;207.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR123_26</td><td>BibArticle</td><td>Hershberger PA, et al. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7(4):1043&#8211;51.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR124_26</td><td>BibArticle</td><td>Huang YC, Chen JY, Hung WC. Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Oncogene 2004;23(28):4856&#8211;61.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1207621>10.1038/sj.onc.1207621</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, JournalTitle, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR125_26</td><td>BibArticle</td><td>Inoue T, Kamiyama J, Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999;274(45):32309&#8211;17.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR126_26</td><td>BibArticle</td><td>Lin R, et al. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinology 2003;144(3):749&#8211;53.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR127_26</td><td>BibArticle</td><td>Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278(47):46862&#8211;8.</td><td><a href=http://dx.doi.org/10.1074/jbc.M306340200>10.1074/jbc.M306340200</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR128_26</td><td>BibArticle</td><td>Kobayashi T, Hashimoto K, Yoshikawa K. Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 1993;196(1):487&#8211;93.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1993.2276>10.1006/bbrc.1993.2276</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID, IssueID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR129_26</td><td>BibArticle</td><td>Fan FS, Yu WC. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest 1995;13(3):280&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR130_26</td><td>BibArticle</td><td>Hager G, et al. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 2001;121(1):103&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR131_26</td><td>BibArticle</td><td>Jensen SS, et al. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001;15(8):1370&#8211;80.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR132_26</td><td>BibArticle</td><td>Yen A, Varvayanis S. Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp Cell Res 1994;214(1):250&#8211;7.</td><td><a href=http://dx.doi.org/10.1006/excr.1994.1255>10.1006/excr.1994.1255</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR133_26</td><td>BibArticle</td><td>Matsumoto K, et al. Growth-inhibitory effects of 1,25-dihydroxyvitamin D3 on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun 1990;166(2):916&#8211;23.</td><td><a href=http://dx.doi.org/10.1016/0006-291X(90)90898-W>10.1016/0006-291X(90)90898-W</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR134_26</td><td>BibArticle</td><td>Reitsma PH, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983;306(5942):492&#8211;4.</td><td><a href=http://dx.doi.org/10.1038/306492a0>10.1038/306492a0</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, FirstPage, VolumeID, IssueID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR135_26</td><td>BibArticle</td><td>Tong WM, et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998;34(13):2119&#8211;25.</td><td><a href=http://dx.doi.org/10.1016/S0959-8049(98)00267-6>10.1016/S0959-8049(98)00267-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR136_26</td><td>BibArticle</td><td>Drivdahl RH, et al. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995;26(2):72&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/pros.2990260203>10.1002/pros.2990260203</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR137_26</td><td>BibArticle</td><td>Scharla SH, et al. 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology 1991;129(6):3139&#8211;46.</td><td><a href=http://dx.doi.org/10.1210/endo-129-6-3139>10.1210/endo-129-6-3139</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR138_26</td><td>BibArticle</td><td>Vink-van Wijngaarden T, et al. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089. Eur J Cancer 1996;32A(5):842&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/0959-8049(95)00647-8>10.1016/0959-8049(95)00647-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR139_26</td><td>BibArticle</td><td>Haugen JD, et al. 1 Alpha,25-dihydroxyvitamin D3 inhibits normal human keratinocyte growth by increasing transforming growth factor beta 2 release. Biochem Biophys Res Commun 1996;229(2):618&#8211;23.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR140_26</td><td>BibArticle</td><td>Wu Y, et al. 1 Alpha,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res Commun 1997;239(3):734&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR141_26</td><td>BibArticle</td><td>Elstner E, et al. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995;55(13):2822&#8211;30.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR142_26</td><td>BibArticle</td><td>Studzinski GP, et al. Uncoupling of cell cycle arrest from the expression of monocytic differentiation markers in HL60 cell variants. Exp Cell Res 1997;232(2):376&#8211;87.</td><td><a href=http://dx.doi.org/10.1006/excr.1997.3484>10.1006/excr.1997.3484</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR143_26</td><td>BibArticle</td><td>Qiao S, Tuohimaa P. Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells. FEBS Lett 2004;577(3):451&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR144_26</td><td>BibArticle</td><td>Qiao S, Tuohimaa P. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Biochem Biophys Res Commun 2004;319(2):358&#8211;68.</td><td><a href=http://dx.doi.org/10.1016/j.bbrc.2004.05.014>10.1016/j.bbrc.2004.05.014</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR145_26</td><td>BibArticle</td><td>Bao BY, et al. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004;23(19):3350&#8211;60.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1207461>10.1038/sj.onc.1207461</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR146_26</td><td>BibArticle</td><td>Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002;1(9):667&#8211;77.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR147_26</td><td>BibArticle</td><td>Modzelewski RA, Hershberger PA, Johnson CS, et al. Apoptotic effects of paclitaxel and calcitriol in rat dunning MLL and human PC-3 prostate tumors in vitro. Proc AACR 1999;40:580.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR148_26</td><td>BibArticle</td><td>Elstner E, et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 1996;56(15):3570&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR149_26</td><td>BibArticle</td><td>James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996;58(4):395&#8211;401.</td><td><a href=http://dx.doi.org/10.1016/0960-0760(96)00048-9>10.1016/0960-0760(96)00048-9</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR150_26</td><td>BibArticle</td><td>Pepper C, et al. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003;101(7):2454&#8211;60.</td><td><a href=http://dx.doi.org/10.1182/blood-2002-07-1984>10.1182/blood-2002-07-1984</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, VolumeID, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR151_26</td><td>BibChapter</td><td>Sergeev INRW, Norman AW. 1,25-dihydroxyvitamin D3, intracellular Ca2+ and apoptosis in breast cancer cell lines. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D chemistry, biology and clinical applications of the steroid hormone. Riverside, CA: University of California; 1997. p. 473&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR152_26</td><td>BibArticle</td><td>Simboli-Campbell M, et al. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 1996;58(4):367&#8211;76.</td><td><a href=http://dx.doi.org/10.1016/0960-0760(96)00055-6>10.1016/0960-0760(96)00055-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR153_26</td><td>BibArticle</td><td>Vandewalle B, Wattez N, Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 1995;97(1):99&#8211;106.</td><td><a href=http://dx.doi.org/10.1016/0304-3835(95)03958-Y>10.1016/0304-3835(95)03958-Y</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR154_26</td><td>BibArticle</td><td>Wagner N, et al. 1,25-Dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res 2003;77(1):1&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0014-4835(03)00108-8>10.1016/S0014-4835(03)00108-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, IssueID, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR155_26</td><td>BibArticle</td><td>Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 1999;59(19):4848&#8211;56.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR156_26</td><td>BibArticle</td><td>Polek TC, et al. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003;144(1):50&#8211;60.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR157_26</td><td>BibArticle</td><td>Galbiati F, et al. Molecular pathways involved in the antineoplastic effects of calcitriol on insulinoma cells. Endocrinology 2003;144(5):1832&#8211;41.</td><td><a href=http://dx.doi.org/10.1210/en.2002-221014>10.1210/en.2002-221014</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, IssueID, VolumeID, FirstPage, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR158_26</td><td>BibArticle</td><td>Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 2001;276(12):9101&#8211;7.</td><td><a href=http://dx.doi.org/10.1074/jbc.M006876200>10.1074/jbc.M006876200</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, VolumeID, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR159_26</td><td>BibArticle</td><td>Xie SP, James SY, Colston KW. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997;154(3):495&#8211;504.</td><td><a href=http://dx.doi.org/10.1677/joe.0.1540495>10.1677/joe.0.1540495</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, IssueID, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR160_26</td><td>BibArticle</td><td>Bernardi RJ, et al. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001;7(12):4164&#8211;73.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR161_26</td><td>BibArticle</td><td>Bernardi RJ, et al. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002;143(7):2508&#8211;14.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR162_26</td><td>BibArticle</td><td>Rocker D, et al. 1,25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol 1994;106(1&#8211;2):157&#8211;62.</td><td><a href=http://dx.doi.org/10.1016/0303-7207(94)90198-8>10.1016/0303-7207(94)90198-8</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR163_26</td><td>BibArticle</td><td>Murthy S, Weigel NL. 1Alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 2004;59(3):282&#8211;91.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR164_26</td><td>BibArticle</td><td>Sergeev IN, Rhoten WB. Regulation of intracellular calcium in human breast cancer cells. Endocrine 1998;9(3):321&#8211;7.</td><td><a href=http://dx.doi.org/10.1385/ENDO:9:3:321>10.1385/ENDO:9:3:321</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR165_26</td><td>BibArticle</td><td>Sergeev IN. Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. J Steroid Biochem Mol Biol 2004;89&#8211;90(1&#8211;5):419&#8211;25.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2004.03.010>10.1016/j.jsbmb.2004.03.010</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR166_26</td><td>BibArticle</td><td>Jiang F, et al. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004;279(51):53213&#8211;21.</td><td><a href=http://dx.doi.org/10.1074/jbc.M410395200>10.1074/jbc.M410395200</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR167_26</td><td>BibArticle</td><td>De Haes P, et al. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J Cell Biochem 2003;89(4):663&#8211;73.</td><td><a href=http://dx.doi.org/10.1002/jcb.10540>10.1002/jcb.10540</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR168_26</td><td>BibArticle</td><td>Mantell DJ, et al. 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87(3):214&#8211;20.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR169_26</td><td>BibArticle</td><td>Majewski S, et al. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig Dermatol Symp Proc 1996;1(1):97&#8211;101.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR170_26</td><td>BibArticle</td><td>Yudoh K, Matsuno H, Kimura T. 1Alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999;133(2):120&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR171_26</td><td>BibArticle</td><td>Schwartz GG, et al. 1 Alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997;6(9):727&#8211;32.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR172_26</td><td>BibArticle</td><td>Sung V, Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol 2000;164(1&#8211;2):133&#8211;43.</td><td><a href=http://dx.doi.org/10.1016/S0303-7207(00)00226-4>10.1016/S0303-7207(00)00226-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR173_26</td><td>BibArticle</td><td>Bao BY, Yeh SD, Lee YF. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006;27(1):32&#8211;42.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR174_26</td><td>BibArticle</td><td>Hansen CM, et al. 1 Alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994;12(3):195&#8211;202.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR175_26</td><td>BibArticle</td><td>Young MR, et al. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 1995;41(1):37&#8211;45.</td><td><a href=http://dx.doi.org/10.1007/BF01788958>10.1007/BF01788958</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR176_26</td><td>BibArticle</td><td>Koli K, Keski-Oja J. 1Alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000;11(4):221&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR177_26</td><td>BibArticle</td><td>Campbell MJ, et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997;19(1):15&#8211;27.</td><td><a href=http://dx.doi.org/10.1677/jme.0.0190015>10.1677/jme.0.0190015</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR178_26</td><td>BibArticle</td><td>Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A, et al. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett 1998;426(2):225&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR179_26</td><td>BibArticle</td><td>Yu WD, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998;90(2):134&#8211;41.</td><td><a href=http://dx.doi.org/10.1093/jnci/90.2.134>10.1093/jnci/90.2.134</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR180_26</td><td>BibArticle</td><td>Beer TM, et al. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49&#8211;55.</td><td><a href=http://dx.doi.org/10.1016/S0093-7754(01)90155-1>10.1016/S0093-7754(01)90155-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR181_26</td><td>BibArticle</td><td>Moffatt KA, Johannes WU, Miller GJ. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 1999;5(3):695&#8211;703.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR182_26</td><td>BibArticle</td><td>Ahmed S, et al. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 2002;168(2):756&#8211;61.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64740-4>10.1016/S0022-5347(05)64740-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR183_26</td><td>BibArticle</td><td>Light BW, et al. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 1997;57(17):3759&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR184_26</td><td>BibArticle</td><td>Wieder R, et al. 1,25-Dihydroxyvitamin D3 and all-trans retinoic acid promote apoptosis and sensitize breast cancer cells to the effects of chemotherapeutic agents. Proc Am Soc Clin Oncol 1998;17:107a.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR185_26</td><td>BibArticle</td><td>Sundaram S, et al. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 2000;63(1):1&#8211;10.</td><td><a href=http://dx.doi.org/10.1023/A:1006420708806>10.1023/A:1006420708806</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, JournalTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR186_26</td><td>BibArticle</td><td>Torres R, et al. Etoposide stimulates 1,25-dihydroxyvitamin D3 differentiation activity, hormone binding and hormone receptor expression in HL-60 human promyelocytic cells. Mol Cell Biochem 2000;208(1&#8211;2):157&#8211;62.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR187_26</td><td>BibArticle</td><td>Koga M, Sutherland RL. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 1991;39(4A):455&#8211;60.</td><td><a href=http://dx.doi.org/10.1016/0960-0760(91)90238-Z>10.1016/0960-0760(91)90238-Z</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR188_26</td><td>BibArticle</td><td>Guzey M, Sattler C, DeLuca HF. Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochem Biophys Res Commun 1998;249(3):735&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR189_26</td><td>BibArticle</td><td>Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):307&#8211;15.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2004.10.006>10.1016/j.jsbmb.2004.10.006</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR190_26</td><td>BibArticle</td><td>Ikeda N, et al. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2003;2(8):739&#8211;46.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR191_26</td><td>BibArticle</td><td>Anzano MA, et al. 1 Alpha,25-dihydroxy-16-ene-23-yne-26, 27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res 1994;54(7):1653&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR192_26</td><td>BibArticle</td><td>Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994;72(11&#8211;12):537&#8211;45.</td><td><a href=http://dx.doi.org/10.1139/o94-072>10.1139/o94-072</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR193_26</td><td>BibArticle</td><td>Abe-Hashimoto J, et al. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993;53(11):2534&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR194_26</td><td>BibArticle</td><td>Christensen GL, et al. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat 2004;85(1):53&#8211;63.</td><td><a href=http://dx.doi.org/10.1023/B:BREA.0000021047.37869.95>10.1023/B:BREA.0000021047.37869.95</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, JournalTitle, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR195_26</td><td>BibArticle</td><td>Gavrilov V, Steiner M, Shany S. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Res 2005;25(5):3425&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR196_26</td><td>BibArticle</td><td>Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J Steroid Biochem Mol Biol 2005;97(1&#8211;2):31&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2005.06.012>10.1016/j.jsbmb.2005.06.012</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR197_26</td><td>BibArticle</td><td>Moreno J, et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005;65(17):7917&#8211;25.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR198_26</td><td>BibArticle</td><td>Hsiao M, et al. Functional expression of human p21(WAF1/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. Biochem Biophys Res Commun 1997;233(2):329&#8211;35.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR199_26</td><td>BibArticle</td><td>Dunlap N, et al. 1Alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. Br J Cancer 2003;89(4):746&#8211;53.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR200_26</td><td>BibArticle</td><td>Polar MK, et al. Effect of the vitamin D3 analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother Pharmacol 2003;51(5):415&#8211;21.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR201_26</td><td>BibArticle</td><td>DeMasters GA, et al. Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the vitamin D3 analog EB 1089. J Steroid Biochem Mol Biol 2004;92(5):365&#8211;74.</td><td><a href=http://dx.doi.org/10.1016/j.jsbmb.2004.07.011>10.1016/j.jsbmb.2004.07.011</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR202_26</td><td>BibArticle</td><td>Osborn JL, et al. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1995;1(5):195&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/1078-1439(95)00061-5>10.1016/1078-1439(95)00061-5</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR203_26</td><td>BibArticle</td><td>Gross C, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159(6):2035&#8211;9. Discussion 2039&#8211;40.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)63236-1>10.1016/S0022-5347(01)63236-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR204_26</td><td>BibArticle</td><td>Smith DC, et al. A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999;5(6):1339&#8211;45.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR205_26</td><td>BibArticle</td><td>Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001;91(12):2431&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(20010615)91:12%3C2431::AID-CNCR1278%3E3.0.CO;2-3>10.1002/1097-0142(20010615)91:12%3C2431::AID-CNCR1278%3E3.0.CO;2-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR206_26</td><td>BibArticle</td><td>Muindi JR, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 2002;72(6):648&#8211;59.</td><td><a href=http://dx.doi.org/10.1067/mcp.2002.129305>10.1067/mcp.2002.129305</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR207_26</td><td>BibArticle</td><td>Beer TM, et al. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 2005;11(21):7794&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0552>10.1158/1078-0432.CCR-05-0552</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Year, IssueID, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR208_26</td><td>BibArticle</td><td>Beer TM, Javle MM, Henner WD and Trump DL. Pharmacokinetics (PK) and tolerability of DN-101, a new formulation of calcitriol, in patients with cancer. Proc Amer Assoc Cancer Res 2004;45:404.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR209_26</td><td>BibArticle</td><td>Morris MJ, et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 2004;100(9):1868&#8211;75.</td><td><a href=http://dx.doi.org/10.1002/cncr.20185>10.1002/cncr.20185</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, JournalTitle, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR210_26</td><td>BibArticle</td><td>Tiffany NM, et al. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 2005;174(3):888&#8211;92.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000169261.42298.e6>10.1097/01.ju.0000169261.42298.e6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR211_26</td><td>BibArticle</td><td>Beer TM, et al. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003;97(5):1217&#8211;24.</td><td><a href=http://dx.doi.org/10.1002/cncr.11179>10.1002/cncr.11179</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, JournalTitle, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR212_26</td><td>BibArticle</td><td>Trump DL, et al. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006;106(10):2136&#8211;42.</td><td><a href=http://dx.doi.org/10.1002/cncr.21890>10.1002/cncr.21890</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR213_26</td><td>BibArticle</td><td>Beer TM, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21(1):123&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S1078-1439(03)00079-6>10.1016/S1078-1439(03)00079-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR214_26</td><td>BibArticle</td><td>Beer TM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669&#8211;74.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.06.8197>10.1200/JCO.2006.06.8197</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR215_26</td><td>BibArticle</td><td>Attia S, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008;14(8):2437&#8211;43.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-4274>10.1158/1078-0432.CCR-07-4274</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR216_26</td><td>BibArticle</td><td>Upton RA, et al. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003;18(4):750&#8211;8.</td><td><a href=http://dx.doi.org/10.1093/ndt/gfg030>10.1093/ndt/gfg030</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, IssueID, Year, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR217_26</td><td>BibArticle</td><td>Sjoden G, et al. 1 Alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985;178(3):432&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR218_26</td><td>BibArticle</td><td>Beer TM, Garzotto M, Katovic NM. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am J Clin Oncol 2004;27(5):535&#8211;41.</td><td><a href=http://dx.doi.org/10.1097/01.coc.0000136020.27904.9c>10.1097/01.coc.0000136020.27904.9c</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR219_26</td><td>BibArticle</td><td>Flaig TW, et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006;107(2):266&#8211;74.</td><td><a href=http://dx.doi.org/10.1002/cncr.21982>10.1002/cncr.21982</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, IssueID, Year, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR220_26</td><td>BibArticle</td><td>Chan JS, et al. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int 2008;102(11):1601&#8211;6.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2008.08017.x>10.1111/j.1464-410X.2008.08017.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR221_26</td><td>BibArticle</td><td>Kissmeyer AM, et al. Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem Pharmacol 1997;53(8):1087&#8211;97.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0006-2952(96)00816-7>10.1016/S0006-2952(96)00816-7</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR222_26</td><td>BibArticle</td><td>Bouillon R, et al. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol 1995;50(5):577&#8211;83.</td><td><a href=http://dx.doi.org/10.1016/0006-2952(95)00121-F>10.1016/0006-2952(95)00121-F</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR223_26</td><td>BibArticle</td><td>Bouillon R, Okamura WH, Norman AW. Structure&#8211;function relationships in the vitamin D endocrine system. Endocr Rev 1995;16(2):200&#8211;57.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR224_26</td><td>BibArticle</td><td>Gulliford T, et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998;78(1):6&#8211;13.</td><td><a href=http://dx.doi.org/10.1038/bjc.1998.434>10.1038/bjc.1998.434</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, IssueID, Year, FirstPage, Author_FamilyName_1, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR225_26</td><td>BibArticle</td><td>Evans TR, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002;86(5):680&#8211;5.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6600162>10.1038/sj.bjc.6600162</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, VolumeID, Year, IssueID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR226_26</td><td>BibArticle</td><td>Dalhoff K, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 2003;89(2):252&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6601104>10.1038/sj.bjc.6601104</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR227_26</td><td>BibArticle</td><td>Bower M, et al. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991;337(8743):701&#8211;2.</td><td><a href=http://dx.doi.org/10.1016/0140-6736(91)90280-3>10.1016/0140-6736(91)90280-3</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR228_26</td><td>BibArticle</td><td>Liu G, et al. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 2002;8(9):2820&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR229_26</td><td>BibArticle</td><td>Wieder R, et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Invest New Drugs 2003;21(4):445&#8211;52.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>